| 糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析 |
| 投稿时间：2018-10-10 修订日期：2018-12-29 点此下载全文 |
| 引用本文：林莉莉,姚囡囡,吴珏,刘志宏,宋洪涛.糠酸氟替卡松/维兰特罗复方剂治疗哮喘疗效与耐受性的Meta分析[J].药学实践杂志,2019,37(5):473~480 |
| 摘要点击次数: 1183 |
| 全文下载次数: 689 |
|
|
| 中文摘要:目的 比较糠酸氟替卡松/维兰特罗复方剂（FF/VI）与吸入型糖皮质激素单药或联合长效β2受体激动剂治疗哮喘患者的疗效与耐受性差异。方法 计算机检索CNKI、PubMed、Embase、Cochrane Library等数据库，纳入随机对照试验，采用Cochrane系统评价方法进行评价。结果 共纳入10个研究，共9 811例患者。在疗效上，FF/VI组与对照组相比，提高患者的1秒用力呼气量谷值[WMD=0.09，95% CI（0.05，0.13），P=0.000]和哮喘控制测试评分[WMD=0.63，95% CI（0.24，1.03），P=0.002]。在耐受性方面，FF/VI组与对照组相比不增加患者发生与治疗相关不良反应事件风险[RR=1.15，95% CI（0.98，1.36），P=0.000]。结论 用FF/VI治疗哮喘在疗效方面具有优势，且具有良好的耐受性。其每日1次的用药频次可提高患者依从性，值得推荐使用。 |
| 中文关键词:糠酸氟替卡松 维兰特罗 吸入型糖皮质激素 长效β2受体激动剂 哮喘 荟萃分析 |
| |
| Efficacy and safety of fluticasone furoate/vilanterol in patients with asthma: a systematic review by Meta-analysis |
|
|
| Abstract:Objective To evaluate the efficacy and safety of once-daily fluticasone furoate/vilanterol compared with ICS alone or twice-daily ICS/LABA formulations in patients with asthma.Methods Systematic search was performed for randomized controlled trials in the CNKI,PubMed,Embase and Cochrane Library.Results 10 citations contained 9 811 patients with asthma met the selection criteria. In terms of efficacy,compared with the control group,the patient's trough forced expiratory volume in one second[WMD=0.09,95% Cl(0.05,0.13) P=0.000] and asthma control Test score[WMD=0.63,95% CI(0.24,1.03),P=0.002] were increased in the FF/VI group. In terms of safety,the risk of adverse reaction events associated with treatment in patients was not increased in the FF/VI group compared to the control group[RR=1.15,95% CI(0.98,1.36),P=0.000].Conclusion FF/VI had advantages and better tolerance in treating asthma patients. It is recommended to be used for its once-daily use of the frequency,which was the advantage of improving patient adherence. |
| keywords:fluticasone furoate vilanterol ICS LABA asthma Meta-analysis |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
